Abstract
To unravel the mechanisms underlying failure of endocrine therapy of breast cancer, we have previously executed a functional genetic screen and identified the adaptor protein BCAR1 to be causative for tamoxifen resistance. As a consequence of the manifold of interactions with other proteins, we characterized the contribution of individual protein domains of BCAR1 to anti-estrogen-resistant proliferation of human breast cancer cells. We took advantage of the observation that the closely related family member HEF1 was unable to support long-term anti-estrogen-resistant cell proliferation. Chimerical proteins containing defined domains of BCAR1 and HEF1 were evaluated for anti-estrogen-resistant growth. Exchange of the SH3 and C-terminal domains did not modify the capacity to support cell proliferation. Full support of anti-estrogen resistant proliferation was observed for chimerical molecules containing the central part of BCAR1. The bi-partite SRC-binding site or the Serine-rich domain did not explain the differential capacity of BCAR1. These findings indicate that the differences between BCAR1 and HEF1 with respect to support of anti-estrogen resistance reside in the substrate domain which contains multiple sites for tyrosine phosphorylation. The crucial interactions required for anti-estrogen resistance occur within the substrate domain of BCAR1. Further deciphering of these interactions may resolve the growth regulatory mechanism and provide an explanation for the observation that primary tumors with high levels of BCAR1 are likely to fail on tamoxifen therapy. This information may also help to devise alternative personalized treatment strategies with improved outcome for breast cancer patients.
Similar content being viewed by others
References
Group Early Breast Cancer Trialists’ Collaborative (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
Jaiyesimi IA, Buzdar AU, Decker DA et al (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13:513–529
Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101–112
Clarke R, Liu MC, Bouker KB et al (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316–7339
Osborne CK, Shou J, Massarweh S et al (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s–870s
Lewis JS, Jordan VC (2005) Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591:247–263
Riggins RB, Schrecengost RS, Guerrero MS et al (2007) Pathways to tamoxifen resistance. Cancer Lett 256:1–24
Dorssers LCJ, Van Agthoven T, Dekker A et al (1993) Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. Mol Endocrinol 7:870–878
Van Agthoven T, Veldscholte J, Smid M et al (2009) Functional screen identifies genes associated with human breast cancer progression. Breast Cancer Res Treat 114:23–30
Sakai R, Iwamatsu A, Hirano N et al (1994) A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation- dependent manner. EMBO J 13:3748–3756
Sakai R, Iwamatsu A, Hirano N et al (1994) Characterization, partial purification, and peptide sequencing of p130, the main phosphoprotein associated with v-Crk oncoprotein. J Biol Chem 269:32740–32746
Brinkman A, Van der Flier S, Kok EM et al (2000) BCAR1, a human homologue of the adapter protein p130Cas and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 92:112–120
Ta HQ, Thomas KS, Schrecengost RS et al (2008) A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Res 68:8796–8804
Van der Flier S, Brinkman A, Look MP et al (2000) Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 92:120–127
Van der Flier S, Van der Kwast TH, Claassen CJC et al (2001) Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue. Int J Biol Markers 16:172–178
Van der Flier S, Chan CMW, Brinkman A et al (2000) BCAR1/p130Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas. Int J Cancer 89:465–468
Grebenchtchikov N, Brinkman A, Van Broekhoven SPJ et al (2004) Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue. Clin Chem 50:1356–1363
Dorssers LCJ, Grebenchtchikov N, Brinkman A et al (2004) The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 10:6194–6202
O’Neill GM, Fashena SJ, Golemis EA (2000) Integrin signalling: a new cas(t) of characters enters the stage. Trends Cell Biol 10:111–119
Bouton AH, Riggins RB, Bruce-Staskal PJ (2001) Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene 20:6448–6458
Singh MK, Dadke D, Nicolas E et al (2008) A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol Biol Cell 19:1627–1636
Cabodi S, Moro L, Baj G et al (2004) p130Cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells. J Cell Sci 117:1603–1611
Defilippi P, Di Stefano P, Cabodi S (2006) p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 16:257–263
Riggins RB, Thomas KS, Ta HQ et al (2006) Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 66:7007–7015
Cabodi S, Tinnirello A, Di Stefano P et al (2006) p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res 66:4672–4680
Honda H, Oda H, Nakamoto T et al (1998) Cardiovascular anomaly, impaired actin bundling and resistance to Src- induced transformation in mice lacking p130Cas. Nat Genet 19:361–365
Kim M, Gans JD, Nogueira C et al (2006) Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269–1281
O’Neill GM, Seo S, Serebriiskii IG et al (2007) A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res 67:8975–8979
Singh M, Cowell L, Seo S et al (2007) Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys 48:54–72
Nakamoto T, Sakai R, Ozawa K et al (1996) Direct binding of C-terminal region of p130Cas to SH2 and SH3 domains of Src kinase. J Biol Chem 271:8959–8965
Burnham MR, Bruce-Staskal PJ, Harte MT et al (2000) Regulation of c-SRC activity and function by the adapter protein CAS. Mol Cell Biol 20:5865–5878
Ruest PJ, Shin NY, Polte TR et al (2001) Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src. Mol Cell Biol 21:7641–7652
Sharma A, Mayer BJ (2008) Phosphorylation of p130Cas initiates Rac activation and membrane ruffling. BMC Cell Biol 9:50
Shen Y, Jia Z, Nagele RG et al (2006) SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells. Cancer Res 66:1543–1552
Shen Y, Khusial PR, Li X et al (2007) SRC utilizes Cas to block gap junctional communication mediated by connexin43. J Biol Chem 282:18914–18921
Patwardhan P, Shen Y, Goldberg GS et al (2006) Individual Cas phosphorylation sites are dispensable for processive phosphorylation by Src and anchorage-independent cell growth. J Biol Chem 281:20689–20697
Cai D, Clayton LK, Smolyar A et al (1999) AND-34, a novel p130Cas-binding thymic stromal cell protein regulated by adhesion and inflammatory cytokines. J Immunol 163:2104–2112
Cai D, Iyer A, Felekkis KN et al (2003) AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter. Cancer Res 63:6802–6808
Gotoh T, Cai D, Tian X et al (2000) p130Cas regulates the activity of AND-34, a novel Ral, Rap1, and R-Ras guanine nucleotide exchange factor. J Biol Chem 275:30118–30123
Riggins RB, Quilliam LA, Bouton AH (2003) Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. J Biol Chem 278:28264–28273
Schrecengost RS, Riggins RB, Thomas KS et al (2007) Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Res 67:6174–6182
Van Agthoven T, Van Agthoven TLA, Dekker A et al (1998) Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17:2799–2808
Van Agthoven T, Van Agthoven TLA, Portengen H et al (1992) Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75–1 human breast cancer cells. Cancer Res 52:5082–5088
Law SF, Zhang YZ, Klein-Szanto AJP et al (1998) Cell cycle-regulated processing of HEF1 to multiple protein forms differentially targeted to multiple subcellular compartments. Mol Cell Biol 18:3540–3551
Riggins RB, DeBerry RM, Toosarvandani MD et al (2003) Src-Dependent Association of Cas and p85 Phosphatidylinositol 3′-Kinase in v-crk-Transformed Cells. Mol Cancer Res 1:428–437
Pawson T (1995) Protein modules and signalling networks. Nature 373:573–580
Garron ML, Arsenieva D, Zhong J et al (2009) Structural insights into the association between BCAR3 and Cas family members, an atypical complex implicated in Anti-oestrogen resistance. J Mol Biol 386:190–203
Law SF, Estojak J, Wang BL et al (1996) Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol 16:3327–3337
Van Agthoven T, Sieuwerts AM, Meijer-Van Gelder ME et al (2009) Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 27:542–549
Nasertorabi F, Tars K, Becherer K et al (2006) Molecular basis for regulation of Src by the docking protein p130Cas. J Mol Recognit 19:30–38
Acknowledgments
We thank all current and past members of the molecular biology research lab for their stimulating support. This study was supported in part by grants of the Association for International Cancer Research (00-38), the Susan G. Komen Breast Cancer Foundation (BCTR0402594), and the Dutch Cancer Society.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brinkman, A., de Jong, D., Tuinman, S. et al. The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells. Breast Cancer Res Treat 120, 401–408 (2010). https://doi.org/10.1007/s10549-009-0403-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-009-0403-4